Dendreon Corporation (NASDAQ NDN) receives authorization and approval from the European Medicines Agency (EMA), Celsion Corporation (NASDAQ:CLSN)

Dendreon Corporation (NASDAQ NDN) is a biotechnology company primarily focusing on treating cancer. The company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics which will transform cancer treatment options into lives.

The company has announced that they have received authorization and approval from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) that PROVENGE can be marketed in the European Union to treat the patients suffering from Asymptomatic or Minimally Symptomatic Metastatic (non-visceral) castrate resistant prostate cancer which are commonly found in male adults and chemotherapy has not yet been clinically indicated in them. The CHMP’s recommendation was supported by a positive recommendation from the Committee for Advanced Therapy (CAT).

Mark Frohlich, the Executive Vice President of R & D and the Chief Medical Officer of Dendreon pleasingly said that they are happy with the outcome and are looking forward to the European Commission‘s final regulatory decision this year. He explained that PROVENGE is a novel therapy which helps the patients to meet their unmet needs, by using one’s own immune system to fight against cancer. He remarked that the said therapy is approved the same will help many lives to live a better healthy life ahead.  This is the first immunotherapy which has resulted in an overall improvement in prostate cancer patients. .

John H. Johnson, Dendreon’s Chairman, President CEO has said that the recommendation as mentioned above represents and signifies that the company is achieving a milestone and the company is engaged in global market opportunity for the said therapy.

Celsion Corporation (NASDAQ:CLSN) is primarily engaged in developing and commercializing certain innovative cancer drugs including tumor treatments which uses a combination of heat energy with heat activated liposomal drug technology. Celsion has certain products lined up which are under their clinical trial namely ThermoDox, in its Phase III being evaluated primarily for liver cancer, a Phase II Colorectal Liver Metastasis (CRLM) and a Phase II for recurrent chest wall breast cancer.